SPONSOR
UNICANCER
Total Trials
4
Recruiting
4
Phases
Phase 2, Phase 3
Conditions studied: Solid Tumor, MiscellaneousLeiomyosarcoma UterusProstatic Cancer, Castration-ResistantOropharynx Squamous Cell Carcinoma
UNICANCER is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Solid Tumor, Miscellaneous, Leiomyosarcoma Uterus, Prostatic Cancer, Castration-Resistant, Oropharynx Squamous Cell Carcinoma.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — UNICANCER
How many clinical trials has UNICANCER sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by UNICANCER, of which 4 are actively recruiting participants. These trials cover conditions including Solid Tumor, Miscellaneous, Leiomyosarcoma Uterus, Prostatic Cancer, Castration-Resistant. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does UNICANCER research focus on?
UNICANCER clinical trials span Solid Tumor, Miscellaneous, Leiomyosarcoma Uterus, Prostatic Cancer, Castration-Resistant, Oropharynx Squamous Cell Carcinoma. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a UNICANCER clinical trial?
To participate in a UNICANCER trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all UNICANCER trials with current recruitment status updated daily.
Clinical Trials by UNICANCER
NCT06653777 Phase 2
Recruiting
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
Solid Tumor, Miscellaneous
NCT06524583 Phase 2
Recruiting
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Leiomyosarcoma Uterus
NCT06276465 Phase 3
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
Prostatic Cancer, Castration-Resistant
NCT05582122 Phase 2
Recruiting
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
Oropharynx Squamous Cell Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology